TREATMENT
Vitamin E or vitamin C supplements did not differ from placebo for major cardiovascular events and mortality
| The first 150 words of the full text of this article appear below. |
H D Sesso
Dr H D Sesso, Brigham and Womens Hospital, Boston, MA, USA; hsesso@hsph.harvard.edu
In men at lower risk of cardiovascular disease (CVD), do vitamin E and vitamin C supplements reduce major CVD events?
Design: randomised placebo controlled trial (Physicians Health Study II). ClinicalTrials.gov NCT00270647 [ClinicalTrials.gov] .
Allocation: unclear allocation concealment.
Blinding: blinded (patients, clinicians, and outcome assessors)
Follow-up period:
10 years (mean 8 y).
Setting: USA.
Patients:
14 641 male physicians
50 years of age (mean age 64 y). Men with a history of myocardial infarction (MI), stroke, or cancer were included. Exclusion criteria were history of cirrhosis, active liver disease, anticoagulant use, or serious illness. 5.1% of men had prevalent CVD.
Intervention:
after stratification for age, previous cancer or CVD diagnosis, and previous β-carotene assignment, men were allocated to vitamin E, 400 IU every other day (n = 3659); vitamin C, 500 mg/day (n = 3673); vitamin E
University of Victoria School of Nursing Victoria, British Columbia, Canada
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
